John Seymour

Should Undetectable Minimal Residual Disease Be the Goal of Chronic Lymphocytic Leukemia Therapy?

Othman Al-Sawaf, John F Seymour, Arnon P Kater, Kirsten Fischer

Journal article  |  2021  |  HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

With the advent of highly effective novel therapies for chronic lymphocytic leukemia, conventional response assessment is not able..

Prospective Phase II trial of radiation therapy in localised non-gastric marginal zone lymphoma with prospective evaluation of autoimmunity and Helicobacter pylori status: TROG 05.02/ALLG NHL15.

Michael P MacManus, Daniel Roos, Peter O'Brien, Anne Capp, Andrew Wirth, Richard Tsang, Mathias Bressel, Stephen Lade, John F Seymour

Journal article  |  2021  |  Eur J Cancer

BACKGROUND: This Phase 2 multicentre trial in localised non-gastric marginal zone lymphoma (MZL) evaluated the effectiveness and s..

Efficacy of venetoclax plus rituximab for relapsed CLL: Five-year follow-up of continuous or limited-duration therapy.

Shuo Ma, John F Seymour, Danielle M Brander, Thomas J Kipps, Michael Y Choi, Mary Ann Anderson, Kathryn Humphrey, Abdullah Al Masud, John Pesko, Ruby Nandam, Ahmed Hamed Salem, Brenda Chyla, Jennifer Arzt, Amanda Jacobson, Su Young Kim, Andrew W Roberts

Journal article  |  2021  |  Blood

We report long-term follow-up of the phase 1b study of venetoclax and rituximab (VenR) in patients with relapsed chronic lymphocyt..

Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase 1, First-in-Human Study.

Matthew S Davids, Andrew W Roberts, Vaishalee P Kenkre, William G Wierda, Abhijeet Kumar, Thomas J Kipps, Michelle Boyer, Ahmed Hamed Salem, John Pesko, Jennifer Arzt, Margaret Mantas, Su Young Kim, John F Seymour

Journal article  |  2021  |  Clin Cancer Res

PURPOSE: We previously reported a 44% overall response rate (ORR) with venetoclax in a phase 1 study of relapsed/refractory NHL. C..

UNFAVORABLE GENETICS IMPACT MRD RESPONSE TO VENETOCLAX RITUXIMAB RETREATMENT IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL): PHASE 3 MURANO SUBSTUDY

JQ Wu, JF Seymour, B Eichhorst, P Hillmen, T Kipps, AW Langerak, C Owen, J Dubois, C Mellink, A van der Kevie‐Kersemaekers, B Chyla, Y Jiang, M Boyer, M Thadani‐Mulero, M Lefebure, AP Kater

Conference Proceedings  |  2021  |  Hematological Oncology

POLATUZUMAB VEDOTIN OBINUTUZUMAB VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): PRIMARY ANALYSIS OF A PHASE 1B/2 TRIAL

R Bannerji, S Yuen, T Phillips, C Arthur, I Isufi, P Marlton, JF Seymour, P Corradini, A Molinari, G Gritti, R Emmons, J Hirata, L Musick, S Saha, B Croft, C Flowers

Conference Proceedings  |  2021  |  Hematological Oncology

FIRST RESULTS OF A HEAD‐TO‐HEAD TRIAL OF ACALABRUTINIB VERSUS IBRUTINIB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA

P Hillmen, JC Byrd, P Ghia, AP Kater, A Chanan‐Khan, RR Furman, S O'Brien, MN Yenerel, A Illes, N Kay, JA Garcia‐Marco, A Mato, J Pinilla‐Ibarz, JF Seymour, S Lepretre, S Stilgenbauer, T Robak, P Patel, K Higgins, S Sohoni, et al.

Conference Proceedings  |  2021  |  Hematological Oncology

Evaluation of the Impact of Magnetic Resonance Imaging with Susceptibility-weighted Imaging for Screening and Surveillance of Radiation-induced Cavernomas in Long-term Survivors of Malignancy.

BA Campbell, A Lasocki, SF Oon, M Bressel, N Goroncy, M Dwyer, K Wiltshire, JF Seymour, K Mason, D Tange, M Xu, G Wheeler

Journal article  |  2021  |  Clin Oncol (R Coll Radiol)

AIMS: Radiation-induced cavernomas (RIC) are common late toxicities in long-term survivors of malignancy following cerebral irradi..

Polatuzumab vedotin obinutuzumab venetoclax in patients with relapsed/refractory (R/R) follicular lymphoma (FL): Primary analysis of a phase 1b/2 trial.

Rajat Bannerji, Sam Yuen, Tycel Jovelle Phillips, Christopher Arthur, Iris Isufi, Paula Marlton, John Francis Seymour, Paolo Corradini, Annalia Molinari, Giuseppe Gritti, Robert Emmons, Jamie Hirata, Lisa Musick, Sourish Saha, Brandon Croft, Christopher Flowers

Conference Proceedings  |  2021  |  Journal of Clinical Oncology

7534 Background: Polatuzumab vedotin (Pola) + obinutuzumab (G) demonstrated activity and tolerability in a Phase 1b/2 trial of pa..

First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia.

John C Byrd, Peter Hillmen, Paolo Ghia, Arnon P Kater, Asher Alban Akmal Chanan-Khan, Richard R Furman, Susan M O'Brien, Mustafa Nuri Yenerel, Árpád Illés, Neil E Kay, Jose Antonio Garcia Marco, Anthony R Mato, John Francis Seymour, Stephane Leprêtre, Stephan Stilgenbauer, Tadeusz Robak, Priti Patel, Kara Higgins, Sophia Sohoni, Wojciech Jurczak

Conference Proceedings  |  2021  |  Journal of Clinical Oncology

7500 Background: Increased selectivity of the Bruton tyrosine kinase inhibitor (BTKi) acalabrutinib (Aca) vs ibrutinib (Ib) may i..